Home » Topics » Respiratory, BioWorld Science

Respiratory, BioWorld Science
RSS

Orally active MDP derivative as lead for antiallergic compounds

June 23, 1997

Labopharm and Sepracor to develop new dosage forms of levalbuterol

June 20, 1997

PPL Therapeutics authorized to start phase II trials with transgenic product

June 18, 1997

Dainippon Ink presents new antiallergic/antiasthmatic agent

June 18, 1997

New asthma treatment now available in Canada

June 17, 1997

Milkhaus receives FDA approval to start phase II cystic fibrosis trial

June 17, 1997

IND for gene therapy for cystic fibrosis approved

June 13, 1997

NIH funds high-throughput screening in allergic inflammation and immunology by Cadus

June 11, 1997

Inflazyme granted Australian patent for antiinflammatory agents

June 9, 1997

Aciclovir demonstrates antiasthmatic activity in animal model

June 9, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.